Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05325151 · ClinicalTrials.gov registry record · NA

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

A NA study of Breast Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
NA
Development phase
874
Enrollment target
1
Study location

NCT05325151: Active NA study of Breast Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.

NCT05325151 is a NA study of Breast Carcinoma that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 874 participants, above the 762-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (15% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05325151, a NA study of Breast Carcinoma, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
874 participants
Enrollment target
1
Study location

Study Summary

This stage I clinical trial compares a genetic counseling patient preference (GCPP) intervention via EHR MyChart patient portal to conventional genetic counseling for women at elevated risk for breast cancer. Women at elevated breast cancer risk may be offered genetic counseling and genetic testing to further define whether they are at high risk (e.g. hereditary risk; BRCA mutation positive); moderate risk (e.g. risk based largely on family history and/or polygenic risk score) or average risk (e.g. general population). Genetic counseling may improve basic genetic knowledge, produce more accurate risk perceptions and tailor recommendations for greater perceived personal control regarding breast cancer risk. A single approach to genetic counseling may not fit the needs for all patients, and genetic counseling models that increase access to genetic testing and are more patient-centered may better serve patients. This trial may help researchers determine if a GCPP intervention can take the place of conventional genetic counseling, while being non-inferior in terms of adherence to screening recommendations, breast cancer genetic knowledge, accurate perception of risk, breast cancer-specific worry, and satisfaction with counseling compared to conventional genetic counseling. Study results will provide the efficacy for using a novel cancer genetic counseling approach via EHR MyChart patient portal that will be readily adaptable to other health care systems in the future, inform best practices, and reduce workforce burden.

Primary Outcome

Non-inferiority will be assessed by constructing a one-sided 95% confidence interval for the effect of genetic counseling patient preference (GCCP) versus conventional counseling and comparing the bound to a non-inferiority margin. Will use mixed effects logistic regression with adherence as the outcome, random intercept effects for genetic counselors, and fixed effects for study arm, breast cancer knowledge, breast cancer worry, post-test/counseling distress, and perception of breast cancer ris

Conditions Studied

Interventions

  • OTHER Survey Administration
  • OTHER Educational Intervention
  • OTHER Genetic Counseling

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 874 participants
Start Date 2022-06-13
Est. Completion 2026-03-30
Phase NA

What the registry record for NCT05325151 still lists

NCT05325151 is an interventional study that assigns participants to a tested intervention. The registered 874 participants enrollment target is mid-sized for trials with a published cap, above the 762-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (15% higher).

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.

NCT05325151 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05325151 about?

NCT05325151 is a clinical study titled "Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer". This stage I clinical trial compares a genetic counseling patient preference (GCPP) intervention via EHR MyChart patient portal to conventional genetic counseling for women at elevated risk for breast cancer. Women at elevated breast cancer risk may be offered genetic counseling and genetic testing ...

What is the current status of trial NCT05325151?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 874 participants. The study started on 2022-06-13. Estimated completion is 2026-03-30.

What conditions does trial NCT05325151 study?

This clinical trial studies the following conditions: Breast Carcinoma.

What interventions are being tested in trial NCT05325151?

The interventions under investigation include: Survey Administration (OTHER), Educational Intervention (OTHER), Genetic Counseling (OTHER).

Who is sponsoring clinical trial NCT05325151?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05325151 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05325151's enrollment target sits among peer trials

874 14th of 106 higher than 93 of 106 other Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07076199 · 877 participants · Phase 3

    A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  • NCT06627647 · 878 participants · Phase 3

    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

  • NCT04097145 · 870 participants · NA

    Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • NCT06822790 · 869 participants · Phase 3

    Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05325151, the US trial registry maintained by the National Library of Medicine. NCT05325151 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.